---
figid: PMC3380363__nihms322806f1
figlink: /pmc/articles/PMC3380363/figure/F1/
number: F1
caption: Oncogenic signaling pathways regulated by NO and PP2A. NO activates numerous
  signaling pathways associated with cancer cell proliferation, survival, chemoresistance
  and migration. Some of the molecular and pathway targets of NO signaling include
  sGC, HIF-1α, Src, PI3K/Akt, EGFR, Ras, c-Myc and ERK-1/2. Furthermore, NO activates
  oncogenic pathways by redundant mechanisms; for example, ERK-1/2 is activated from
  either Ras signaling or sGC activation and PI3K/Akt signaling is activated by either
  EGFR or Src kinases. These redundant mechanisms indicate that single agent therapies
  could fail to limit oncogenic NO signaling. The tumor suppressor PP2A is the endogenous
  negative regulator of many NO-activated signaling pathways. We propose that pharmacological
  activation of PP2A could represent an effective strategy to limit the myriad of
  pro-tumor NO effects.
pmcid: PMC3380363
papertitle: Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities
  in ER-negative breast cancer.
reftext: Christopher H. Switzer, et al. Trends Pharmacol Sci. ;32(11):644-651.
pmc_ranked_result_index: '10663'
pathway_score: 0.9678302
filename: nihms322806f1.jpg
figtitle: Oncogenic signaling pathways regulated by NO and PP2A
year: ''
organisms:
- Rattus norvegicus
- Betapolyomavirus macacae
- Polyomavirus sp.
- Plasmodium falciparum
- Citrobacter rodentium
- Homo sapiens
ndex: b39cc35a-de95-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3380363__nihms322806f1.html
  '@type': Dataset
  description: Oncogenic signaling pathways regulated by NO and PP2A. NO activates
    numerous signaling pathways associated with cancer cell proliferation, survival,
    chemoresistance and migration. Some of the molecular and pathway targets of NO
    signaling include sGC, HIF-1α, Src, PI3K/Akt, EGFR, Ras, c-Myc and ERK-1/2. Furthermore,
    NO activates oncogenic pathways by redundant mechanisms; for example, ERK-1/2
    is activated from either Ras signaling or sGC activation and PI3K/Akt signaling
    is activated by either EGFR or Src kinases. These redundant mechanisms indicate
    that single agent therapies could fail to limit oncogenic NO signaling. The tumor
    suppressor PP2A is the endogenous negative regulator of many NO-activated signaling
    pathways. We propose that pharmacological activation of PP2A could represent an
    effective strategy to limit the myriad of pro-tumor NO effects.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CTNNB1
  - ARNT2
  - HIF1A
  - PIK3CA
  - SGCB
  - EPAS1
  - HIF3A
  - HRAS
  - PIK3R3
  - ARNT
  - PIK3R6
  - PIK3R5
  - MAPK1
  - KRAS
  - PIK3CB
  - PIK3CD
  - EGFR
  - PIK3CG
  - AKT3
  - AKT2
  - AKT1
  - SRC
  - ARNTL
  - MYC
  - NRAS
  - PIK3R4
  - Cancer
genes:
- word: B-catenin
  symbol: beta-catenin
  source: hgnc_alias_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT2
  entrez: '9915'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: PI3K/Akt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: SGC
  symbol: SGC
  source: hgnc_alias_symbol
  hgnc_symbol: SGCB
  entrez: '6443'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K/Akt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT
  entrez: '405'
- word: PI3K/Akt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K/Akt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: ERK-1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PI3K/Akt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K/Akt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K/Akt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K/Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K/Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K/Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Src
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNTL
  entrez: '406'
- word: C-myc
  symbol: c-Myc
  source: hgnc_alias_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K/Akt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC3380363__F1
redirect_from: /figures/PMC3380363__F1
figtype: Figure
---
